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In the last few years much attention has been focused on the implementation of human papillomavirus detection in population
based screening programmes to identify women at risk for cervical cancer. Short-term ﬂuctuations in prevalence of human
papillomavirus were investigated within a single menstrual cycle. The highest prevalence was found at the follicular phase
(55%), whereas the cumulative prevalence was 75%.
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Epidemiological and molecular studies over the past two decades
have convincingly demonstrated that certain types of human papil-
lomavirus (HPV) are etiologically related to the development of
most cases of cervical cancer (Schiffman et al, 1993; Chichareon
et al, 1998; Ngelangel et al, 1998; Liaw et al, 1999; Walboomers
et al, 1999; Andersson et al, 2001; Lehtinen et al, 2001). A systema-
tic review on the role of HPV testing within a cervical cancer
screening program showed that the high risk HPV prevalence in
CIN 1 ranged from 30 to 65%, in CIN 2 from 40 to 70% and
in CIN 3 from 60 to 90% (Cuzick et al, 1999). Furthermore,
HPV can be detected in almost all cervical carcinomas (Walboo-
mers et al, 1999).
The estimated point prevalences of genital HPV infections
detected by PCR based methods among populations of women
with cytological normal cervical smears range from 1.5 to 44.3%,
with a weighted average of 16.2% (Xi and Koutsky, 1997) and
show an age-related pattern (Melkert et al, 1993). The highest
prevalences are found in women in their early twenties (de Villiers
et al, 1992; Melkert et al, 1993). Newly acquired genital HPV is
usually transient in women with normal cervical cytology (Evander
et al, 1995). The mean duration of cervical HPV infection in a
healthy population varies between 8.2–13.5 months (Ho et al,
1998; Franco et al, 1999). Short-term ﬂuctuations of an individual’s
HPV status, however, are still a matter of debate. Several studies
have reported a ﬂuctuating expression of HPV (Ho et al, 1998;
Schneider et al, 1992; Wheeler et al, 1996), probably due to differ-
ences in viral load, inadequate sampling or reactivation of
endogenous infection (Woodman et al, 2001). Single point
measurements of HPV 16 in cervical smears are of limited value
for assessment of an individual’s HPV status (Schneider et al,
1992).
Before incorporation of HPV testing in screening programs for
prevention of cervical cancer it is important to gain more insight
in the actual prevalence of HPV, inﬂuenced by short-term ﬂuctua-
tions. The aim of this study was to investigate the presence of
cervical HPV in the different phases of a single menstrual cycle
in women with regular cycles.
MATERIALS AND METHODS
Cervical samples for HPV detection and cytological examination
were obtained from 20 women visiting the outpatient clinic for
fertility problems at the University Medical Centre Nijmegen, the
Netherlands. Only women with regular menstrual cycles were
included. Patients with cervical treatment for abnormal cervical
cytology in the past 10 years were not included in the study. After
giving informed consent, patients were interviewed regarding their
medical history, smoking habits, use of contraceptives and sexual
behaviour.
Cervical smears for HPV detection and cytological classiﬁcation
were obtained using the Cervex brush (Rovers, Oss, the Nether-
lands).
On a weekly basis at four visits during their fertility screening
cycle, cervical swabs were taken for HPV detection. The ﬁrst cervi-
cal sample was taken in the menstrual period (2nd or 3rd day of
the cycle), the second sample between the 7th and 11th day of
the cycle, the third sample around ovulation (between the 12th
and 15th day) and the fourth sample in the luteal phase (7 days
post ovulatory, 20th to 24th day). Ovulation was ascertained by
ultrasound examination. Cytological classiﬁcation was done by an
experienced pathologist.
Cervical scrapes were processed into AgarCyto cellblocks as
described by Kerstens et al (2000). HPV detection was assessed
using a short fragment polymerase chain reaction (SPF10-PCR).
HPV genotyping was performed via a reverse hybridisation line
probe assay (LiPA), capable of detecting and genotyping 25 differ-
ent HPV types simultaneously (Kleter et al, 1998, 1999). Statistical
analysis was performed using the chi-square and McNemar tests,
where appropriate. Values of P50.05 were considered to indicate
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in the menstrual cycle.
RESULTS
Eighty cervical smears for HPV testing were obtained from 20
women with a mean age of 33.8+s.d. 4.9 years (range 22–43
years). All women except one were non-smokers. The use of oral
contraceptives was discontinued by all, at least 1 year before
attending our fertility clinic. The mean age of sexarche was
18.6+4.5 years. Nine women had been monogamous since their
sexarche, while the other 11 women were at least monogamous
for the past 2 years. The mean frequency of sexual intercourse
was 2.3 weekly.
Chlamydia serum antibodies were present in four patients. Urine
samples from these four women, obtained to test for an active
chlamydia infection, were all negative.
Three patients (15%) had a history of abnormal cervical smears.
Two of them had ASCUS in 1986 (Table 1, case no. 12, HPV nega-
tive) and in 1996 (Table 1, case no. 10, HPV 33 positive)
respectively. The third woman (Table 1, case no. 6, HPV negative)
was treated in 1984 by a large loop excision of the transformation
zone, which was histologically classiﬁed as severe dysplasia. The
follow-up smears of this patient were normal.
At the end of the study 15 (75%) women appeared to be posi-
tive for HPV at least one time within one menstrual cycle. Single
point measurements of HPV ranged from 20 to 55% (Figure 1).
The cumulative prevalence of oncogenic HPV was 70% (14 out
of 20), with point-prevalences ﬂuctuating between 15 and 45%
(Figure 1).
In the follicular phase (7th to 11th day) a higher rate of HPV
positive samples was found compared to the other phases, which
was signiﬁcantly different according to the chi-square test (P=0.02).
Fifteen different HPV genotypes were detected of which 73.3%
were high risk. Three (15%) patients harboured HPV 16 in their
lower genital tract, whereas ﬁve (25%) women tested positive for
HPV 18 for at least one time within the menstrual cycle (Table
1). Chlamydia serum antibodies were found positive in three
women with HPV 18 in their cervices. Interestingly, HPV 18 was
only detected in the ﬁrst half of the menstrual cycle and never
in the luteal phase.
Five women in the HPV positive group (33.3%) contained
multiple HPV genotypes in one or more of their cervical smears.
In one patient seven different oncogenic HPVs were detected of
which type 56 and 66 were consistently present (Table 1, case
no. 8). She was the youngest participant (22 years) and had her
ﬁrst sexual experience at the age of 14 years. She was monogamous
for the last 2.5 years, but counted at least 10 different sexual part-
ners in the past. The cervical smear of this patient was cytological
classiﬁed as ASCUS.
The only other patient with ASCUS (Table 1, case no. 11) was
positive for HPV 16 in the luteal phase. The cervical smears of
the other 18 women were cytologically diagnosed as normal.
DISCUSSION
In this study, the cumulative prevalence of HPV in infertile, cyto-
logically normal women following weekly consecutive cervical
scrapes during one menstrual cycle was found to be 75%. To
our knowledge this is the highest cumulative prevalence that has
ever been reported for women with normal cervical cytology after
such a short follow-up of only 4 weeks. Several other studies
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Table 1 Individual point prevalences of HPV genotypes in infertile women with normal cervical
cytology
HPV genotypes
Case Day 2–3 Day 7–11 Day 12–15 Day 20–24
1
2
3 18
46 , 52 6, 52 6, 52
5 33
6
7 18 52
8 56, 66 34, 39, 42, 56, 66 6, 18, 34, 39, 42, 56, 66 34, 39, 56, 66
96 6 , 16, 52
10 33
11 6 16
12
13 18 18
14 58
15 18,4 4 18 18
16
17 11 11 11
18 33
19 31, 51
20 16
Bold ﬁgures=high risk HPV.
100%
75%
50%
25%
0%
Day 2–3 Day 7–11 Day 12–15 Day 20–24 Cumulative
*
all HPV
hr HPV
Figure 1 Point-prevalences and cumulative prevalence of HPV during
one menstrual cycle in infertile women. *P50.05 hr=high risk.
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normal women of 34.7 to 66.7% (de Villiers et al, 1992; Schneider
et al, 1992; Wheeler et al, 1996; Ho et al, 1998; Woodman et al,
2001). However, in those studies multiple samples were taken
during study periods of 10 weeks to 5 years in contrast to 4 weeks
in our study (Table 2). Moreover, we studied the prevalence of all
HPV genotypes in contrast to Schneider (only HPV 16) and de
Villiers (HPV 6, 11, 16, 18). In a group of Panama City prostitutes
cumulative HPV prevalence amounted 82% after 8 months with at
least six repeated examinations (Reeves et al, 1989). However, cyto-
logical classiﬁcation of these women was not reported.
In our study, point prevalence of HPV genotypes changed
throughout the menstrual cycle with the highest prevalence in
the follicular phase. From then onwards, single-point HPV preva-
lence decreases until the end of menstruation. Exfoliation of
cervical cells by scraping the surface of the cervix consecutively
every week could have led to a reduction in cells containing
HPV, resulting in a lower prevalence of HPV with every following
smear. However, the initial smears have been made at the menstru-
al period at which the lowest prevalence of HPV was found.
Single time HPV detection rates in our study varied between 20
and 55%, which is comparable to earlier reports (Schneider et al,
1992; Wheeler et al, 1996). It has been postulated that variations
of the single time prevalence are due to differences in viral load.
Viruses can be persistent but undiagnosed because ﬂuctuating
levels of infection around the threshold of detectability (Woodman
et al, 2001).
We found a signiﬁcantly higher prevalence of HPV in the folli-
cular phase, with predominance of HPV 18 (38.4%). Whereas
others found a signiﬁcantly higher prevalence of HPV in the luteal
phase of the cycle (Schneider et al, 1992). However, in this last
study, women were only tested for HPV genotype 16. Wheeler et
al (1996) reported no signiﬁcant correlation in HPV detection
and phase of menstrual cycle, although the point prevalence of
HPV in the follicular phase was higher than in the luteal phase.
Fairley et al (1994) performed a study to determine if HPV detec-
tion or the size of the tampon specimen was effected by the
menstrual cycle. They concluded from their study that the timing
of the menstrual cycle effects the size of tampon specimens but
not the probability of detecting HPV DNA.
The high prevalence of HPV in the follicular phase of our study
group is remarkable. A possible explanation for this ﬁnding is the
physiological widening of the cervical canal in the follicular phase,
resulting in the collection of more or different clinical material
from the deeper layers of the endocervix. This could also be an
explanation for the predominance of HPV 18 in the follicular
phase. After all, in a recent study of the prevalence of HPV in
cervical adenocarcinomas it was demonstrated that HPV 18 was
the most prevalent followed by HPV 16 (Andersson et al, 2001).
It could be argued that fertility problems per se could have led
to a population based bias in HPV prevalence. However, the cervi-
cal HPV prevalence in a group of infertile women undergoing
ovarian stimulation with gonadotrophins varied between 6.8 and
7.8 %, which was similar to 8.4% in the control group (Strehler
et al, 1999).
In women with normal cytological cervical smears, a cumulative
prevalence of HPV as high as 75% in one menstrual cycle has never
been reported. This result suggests that single point detection of
HPV underestimates the true prevalence of HPV in a population.
Sequential scrapes appear to be necessary to determine the true
HPV status in individual cases.
We conclude from our study that detection of HPV on single
sample basis may lead to false negative results. These results may
have important implications for population based HPV screening.
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